



(51) International Patent Classification:

C07D 471/22 (2006.01) A61K 31/429 (2006.01)
C07D 487/12 (2006.01) A61K 31/5025 (2006.01)
C07D 513/22 (2006.01) A61P 35/00 (2006.01)
C07D 519/00 (2006.01)

(21) International Application Number:

PCT/US2021/050454

(22) International Filing Date:

15 September 2021 (15.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/078,802	15 September 2020 (15.09.2020)	US
63/129,231	22 December 2020 (22.12.2020)	US
63/184,412	05 May 2021 (05.05.2021)	US
63/192,775	25 May 2021 (25.05.2021)	US

(71) Applicant: **REVOLUTION MEDICINES, INC.**

[US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **AA Y, Naing**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BUR-**


NETT, Leslie, G.; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CREGG, James**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GILL, Adrian, L.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **KNOX, John, E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **KOLTUN, Elena, S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **LIU, Yang**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BUCKL, Andreas**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **LEE, Bianca, Jennifer**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **WILDES, David, E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **RICE, Meghan, A.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SINGH, Mallika**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.**; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: **INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER**

FIG. 1A



n = 10/group ***p<0.001 All dose levels well tolerated

(57) **Abstract:** The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*